Safety and Efficacy of Obinutuzumab β (MIL62), a Novel Glycoengineered Type II Anti-CD20 Monoclonal Antibody, in Patients with Neuromyelitis Optica Spectrum Disorder: A Multicenter, Single-Arm, Phase Ib Clinical Trial.
Wu L, Wei M, Gao F, Zhang H, Wang J, Xiang F, Gao S, Liu R, Yin J, Guo Y, et al.
